New Work SE

  • WKN: NWRK01
  • ISIN: DE000NWRK013
  • Land: Deutschland

Analyst Coverage

Broker Analyst Empfehlung Traget price
Deutsche Bank Nizla Naizer Hold 276 €
Commerzbank TBA No Rating
Pareto Securities Mark Josefson Hold 257 €
Hauck & Aufhäuser Simon Bentlage Buy 325 €
MM Warburg Marius Fuhrberg Hold 243 €
Berenberg Bank Sarah Simon Hold 234 €

GBC im Fokus

IGEA Pharma N.V. Realignment to CBD extraction

The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.

Aktueller Webcast

Adler Group S.A.

Nine-Month
Investor Call
Q3 2021

30. November 2021

Aktuelle Research-Studie

clearvise AG

Original-Research: clearvise AG (von First Berlin Equity Research GmbH): Buy

30. November 2021